PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

Détails bibliographiques
Auteurs principaux: Murphy, F, Church, D, Medley, L, Davies, J, Breen, D, Clelland, C, Mackintosh, D, Mugalaasi, H, Butler, R, Talbot, D
Format: Journal article
Publié: 2011

Documents similaires